CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 96 enrolled
Drug / intervention
Chartis System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01101958
NCT01101958N/ACompleted

A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) in Subjects With Heterogeneous Emphysema

Pulmonx Corporation·interventional·Posted Apr 12, 2010·Updated May 12, 2017

In Brief

A clinical study evaluating Chartis System and Endobronchial Valve (EBV) Treatment for Emphysema. Completed, enrolled 96 participants across 2 sites in 2 countries.

Detailed Summary

Use of the Chartis® Assessment System prior to EBV Treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmphysema
CountriesGermany, Netherlands
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 12, 2010
Enrollment StartJan 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.2 years ago

Interventions

Chartis Systemdevice

The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.

Endobronchial Valve (EBV) Treatmentdevice

The endobronchial valve is designed to induce target lobe volume reduction.